Dr. Reddy’s Laboratories Ltd, along with its subsidiaries together referred to as “Dr. Reddy’s” announced the launch of Pregabalin Capsulesa therapeutic equivalent generic version of Lyrica®(pregabalin) Capsules approved by the U.S. FDA .
The Lyrica(pregabalin) Capsulesbrand had U.S. sales of approximately $5,462 millionMAT for the most recent twelve months ending in May2019 according to IQVIA Health*.Dr. Reddy’s Pregabalin Capsules are available in 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg capsules in bottle count sizes of 90.
This is also a controlled substance schedule V product. Lyrica is a trademark of C.P. PHARMACEUTICALS INTERNATIONAL C.V
About Dr. Reddy’s:
Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products –Dr. Reddy’s offersa portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include –USA, India, Russia & CIS countries, and Europe. For more information, log on to:www.drreddys.com